This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Carbohydrate-based Subunit Veterinary Vaccine Development
As substances present on the surface of pathogens such as bacteria, parasites, or fungi, carbohydrates can be recognized as foreign by the host immune system and may eventually induce a protective immune response. Since many glycan epitopes are highly pathogen-specific, they are promising candidates for carbohydrate-based vaccines. BioVenic offers veterinary vaccine development services for you, by utilizing carbohydrates as vaccine antigens to defend against bacteria attacks according to your needs.
Our Services
Antigen Discovery
Carbohydrate antigens that stimulate neutralization responses are important targets of the immune system and can inform veterinary vaccine design. BioVenic offers glycan microarray assays to help researchers utilize glycan binding interactions. On a microarray, a large number of structurally distinct glycans from natural or synthetic sources are immobilized on a slide in a spatially defined pattern, a miniaturized format that allows high-throughput screening of hundreds of carbohydrate-protein interactions on a single slide.
Fig.1 Graphical representation of glycan microarray assay.1
Polysaccharide Preparation
Several carbohydrate-based subunit veterinary vaccines composed of natural polysaccharides have demonstrated excellent efficacy and safety in the use. BioVenic offers full process natural polysaccharide extraction services, from pathogen culture to polysaccharide extraction and purification, to ensure that you receive high-quality polysaccharides as antigens.
However, using natural polysaccharides that meet the quality control and safety standards required sometimes may be a little challenging, so BioVenic also offers synthetic polysaccharide services, where synthetic glycans with homogeneous junctions can be used to create well-characterized conjugates in a more cost-effective and reproducible manner that are free of bacterial contaminants.
Formulation Development
BioVenic provides professional vaccine development formulation services aimed at optimizing vaccine formulations to enhance their immunogenicity and protective efficacy. We understand the limitations of polysaccharide antigens and therefore overcome this challenge through clever formulation design and technical optimization.
Adjuvant Optimization
Through appropriate adjuvant selection and optimization, BioVenic enhances the immunostimulatory effects of vaccines to stimulate stronger immune responses, including higher levels of antibody production and immune cell activation.
Stability Testing
We conduct stability testing of our formulations to ensure that they remain stable under different conditions (e.g., temperature, storage time, etc.) to safeguard the quality and efficacy of the vaccine.
Conjugate Veterinary Vaccine Development
BioVenic also provides conjugate veterinary vaccine development services to select the most suitable carrier protein to ensure optimal binding to polysaccharide antigens, thereby improving the immunogenicity of vaccines.
Carbohydrate-based Subunit Veterinary Vaccine Development Services
BioVenic provides subsequent immunogenicity assessment services to test the extent to which the optimization of vaccine formulations improves the immunogenicity of vaccines. At the same time, we conduct detailed toxicity studies and safety assessments to ensure that the vaccine will not cause adverse reactions after vaccination and to protect the safety of vaccinated animals. During the vaccine development process, we conduct strict quality control to ensure the consistency, stability, and safety of the formulations to meet the stringent quality standards.
Why Choose Us?
BioVenic offers polysaccharide antigens from different sources, both natural sources and synthetic, to meet all your needs.
BioVenic provides appropriate vaccine formulation solutions to help your vaccines achieve high immunogenicity.
BioVenic implements suitable quality control measures to guarantee the stability, safety, and uniformity across vaccine batches of carbohydrate-based subunit veterinary vaccines.
In contrast to some other types of veterinary vaccines, carbohydrate-based subunit veterinary vaccines do not contain active pathogens or proteins, thereby reducing the risk of potential adverse reactions in animals. BioVenic also has extensive experience in carbohydrate-based subunit veterinary vaccine development to help you move forward on the path fighting pathogens that infect animals. Contact us now and let's work together for animal health!
Reference
- Durbin, Sarah V.; et al. "Development of a multiplex glycan microarray assay and comparative analysis of human serum anti-glycan IgA, IgG, and IgM repertoires." ACS omega 3.12 (2018): 16882-16891.